SEC Filing Analysis: MAIA Biotechnology, Inc. (MAIA)

Executive Summary

• Trading Significance: Low
• Key Takeaway: Director Cristian Luput was awarded 33,536 stock options with an exercise price of $1.18 as standard board equity compensation.
• Market Impact: Neutral; routine compensation grant with minimal dilution potential.

Company Information

Field	Value
Company	MAIA Biotechnology, Inc.
Ticker Symbol	MAIA
CIK	0001878313
Industry	Pharmaceutical Preparations

Insider Information

Field	Value
Name	Cristian Luput
CIK	0001913350
Title/Position	Director
Relationship	Director

Transaction Details

Field	Value
Form Type	4
Transaction Date	2026-09-30
Transaction Code	A (Award/Grant)
Security Type	Stock Options (Right to Buy)
Shares Involved	33,536
Price Per Share	$0.00 (Exercise price: $1.18)
Total Value	$0.00
Shares Owned After	33,536 derivative contracts
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$0.00 (Exercise value: $39,572.48)
% of Market Cap	<0.01%
Shares Transacted	33,536
% of Shares Outstanding	0.055%
Post-Transaction Ownership	33,536 options (0.055% potential dilution)
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: Across MAIA's $70M market capitalization, this equity grant is standard director remuneration and does not reflect open-market sentiment.
• Ownership Concentration: The options grant accounts for approximately 0.055% of the 60.8M total shares outstanding, posing negligible impact on corporate ownership concentration.
• Dilution Impact: Fully dilutive impact would add only 33,536 shares upon exercise, representing immaterial dilution to existing shareholders.
• Transaction Significance: Classified as Low significance due to small size relative to market cap and shares outstanding.

Market Impact Analysis

• Stock Impact Prediction: Neutral. Standard executive and board compensation awards rarely affect equity valuations or trading trajectories.
• Expected Volume Impact: Negligible expected trading volume reaction.
• Sentiment Indicator: Neutral.

Additional Context

• Timing & Vesting: Granted on September 30, 2026 pursuant to the 2021 Equity Incentive Plan. The options vest 100% on the date of grant with an expiration date of September 30, 2036.